Gryphon Analytics is a leading source of current, data driven news and analysis. With an emphasis on capital markets, corporate development and mergers & acquisitions - Gryphon Analytics provides unique and unbiased insight and analyses to empower thoughtful and practical action for industry managers and officers.
FDA new drug approvals hit 16-year high in 2012 | Reuters
January 3, 2013
U.S. regulators approved 39 new drugs in 2012, the most in 16 years, suggesting that pharmaceutical makers are poised for growth after losing billions of dollars in recent years to generic drug makers because of patent expirations.